HIV Emergency Relief Project Grants

 

To provide direct financial assistance to Eligible Metropolitan Areas (EMAs) and Transitional Grant Areas (TGAs) that have been the most severely affected by the Human Immunodeficiency Virus (HIV) epidemic to enhance access to a comprehensive, effective and cost efficient continuum of high quality, community-based care for low-income individuals and families with HIV and to strengthen strategies to reach minority populations. A comprehensive continuum of care includes the 13 core medical services specified in legislation and appropriate support services that assist people with HIV in accessing treatment for HIV/AIDS that is consistent with the Department of Health and Human Service (HHS) Treatment Guidelines. Comprehensive HIV/AIDS care beyond these core medical services may include support services that meet the criteria of enabling individuals and families with HIV to access and remain in primary medical care to improve their medical outcomes.

Active 93.914 Health Resources and Services Administration, Department of Health and Human Services B - Project Grants Fiscal Year 2016 Nearly 68 percent of all clients served by the RWHAP in 2014 were served in one of the 52 metropolitan areas funded under the RWHAP Part A. Approximately 73 percent of all people living with diagnosed HIV reside in a RWHAP Part A EMA or TGA. Part A funded sites provided 3.7 million core medical service visits for health-related care utilizing a combination of Parts A, B, C, and D funding. The number of visits for health-related services demonstrates the scope of Part A in delivering primary care and related services for PLWH by increasing the availability and accessibility of care. From 2010 to 2015, HIV viral suppression among RWHAP patients has increased from 70 percent to 83 percent, and racial/ethnic, age-based, and regional disparities have decreased. These improved outcomes mean more PLWH in the U.S. will live near normal lifespans and have a reduced risk of transmitting HIV to others. RWHAP Part A jurisdictions are experienced in data-driven, community-based needs assessment, responsive procurement of a variety of direct medical and supportive services, working with a set of providers to weave together a constellation of services, serving diverse populations and continuing to make improvements that positively affect the HIV care continuum. Thus, the RWHAP Part A has a significant public health impact on HIV incidence.
Fiscal Year 2020 According to the 2019 RWHAP Services Report, RWHAP recipients and subrecipients in cities that receive Part A funding provided health care and support services for 371,667 clients (this includes services provided by Part A recipients and subrecipients who receive RWHAP Parts A, B, C and/or D funding). 87.3 percent of RWHAP clients living in Part A jurisdictions, with available data on viral load, achieved viral suppression in 2019. Viral suppression was based on data for people with HIV who had at least one outpatient ambulatory health service visit and at least one viral load test during the measurement year. Viral suppression was defined as the most recent reported HIV RNA test result of <200 copies/mL.
Fiscal Year 2021 RWHAP recipients and subrecipients in cities that receive Part A funding provided health care and support services for 333,683 clients (this includes services provided by Part A recipients and subrecipients who receive RWHAP Parts A, B, C and/or D funding). 88.6 percent of RWHAP clients living in Part A jurisdictions, with available data on viral load, achieved viral suppression in 2020
Fiscal Year 2022 According to the FY 2021 RWHAP Services Report, RWHAP recipients and subrecipients in cities that receive Part A funding provided health care and support services for 337,270 clients (this includes services provided by Part A recipients and subrecipients who receive RWHAP Parts A, B, C and/or D funding). Nearly 90% of outpatient ambulatory health services (OAHS) clients receiving services from RWHAP Part A-funded providers reached viral suppression in 2021. 42 U.S.C. §300ff-11, 300ff-20, and 300ff-121 RWHAP Part A recipients that were classified as an EMA or as a TGA in fiscal year (FY) 2007 and continue to meet the statutory requirements are eligible to apply for these funds; new areas that meet the threshold requirements are also eligible. For an EMA, this is more than 2,000 cases of AIDS reported and confirmed during the most recent five calendar years, and for a TGA, this is at least 1,000, but fewer than 2,000 cases of AIDS reported and confirmed during the most recent period of five calendar years for which such data are available. Additionally, they must not have fallen below, for three consecutive years, the required incidence levels already specified AND required prevalence levels (cumulative total of living cases of AIDS reported to and confirmed by the Director of the Centers for Disease Control and Prevention (CDC) as of December 31 of the most recent calendar year for which such data are available). For an EMA, this is 3,000 living cases of AIDS, and for a TGA, this is 1,500 living cases of AIDS, except certain areas which have a cumulative total of at least 1,400 living cases of AIDS and which have no more than 5 percent of the total from formula grants awarded unobligated as of the end of the most recent fiscal year. Eligible metropolitan areas (EMA) with a population of 50,000 or more individuals for which the CDC has reported a cumulative total of more than 2,000 AIDS cases for the most recent period of 5 calendar years include: Atlanta, Georgia; Baltimore, Maryland; Boston, Massachusetts; Chicago, Illinois; Dallas, Texas; Detroit, Michigan, Ft. Lauderdale, Florida; Houston, Texas; Los Angeles, California; Miami, Florida; Nassau/Suffolk Counties, New York; New Haven, Connecticut; New Orleans, Louisiana; New York, New York; Newark, New Jersey; Orlando, Florida; Philadelphia, Pennsylvania; Phoenix, Arizona; San Diego, California; San Francisco, California; San Juan, Puerto Rico; Tampa-St. Petersburg, Florida; Washington, DC; and West Palm Beach, Florida. Transitional Grant areas (TGA) with a population of 50,000 or more individuals for which the CDC has reported a cumulative total of at least 1,000, but not more than 1,999 AIDS cases for the more most recent five year period include: Austin, Texas; Baton Rouge, Louisiana; Bergen-Passaic, New Jersey; Charlotte, North Carolina; Cleveland, Ohio; Columbus, Ohio; Denver, Colorado; Fort Worth, Texas; Hartford, Connecticut; Indianapolis, Indiana; Jacksonville, Florida; Jersey City, New Jersey; Kansas City, Missouri; Las Vegas, Nevada; Memphis, Tennessee; Middlesex, New Jersey; Minneapolis, Minnesota; Nashville, Tennessee; Norfolk, Virginia; Oakland, California; Orange County, California; Portland, Oregon; Riverside-San Bernardino, California; Sacramento, California; St. Louis, Missouri; San Antonio, Texas; San Jose, California; and Seattle, Washington. Individuals and families living with HIV disease Applicants should review the individual HRSA notice of funding opportunity (NOFO) issued under this assistance listing for any required proof or certifications which must be submitted prior to or simultaneous with submission of an application package. Preapplication coordination is required. This program is eligible for coverage under E.O. 12372, "Intergovernmental Review of Federal Programs." An applicant should consult the office or official designated as the single point of contact in his or her State for more information on the process the State requires to be followed in applying for assistance, if the State has selected the program for review. 2 CFR 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards applies to this program. HRSA requires all applicants to apply electronically through Grants.gov. 45 CFR 75, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards applies to this program. Two-thirds of the funds available are disbursed on a formula basis as required by the legislation, subject to a completeness review of required information specified in the HRSA NOFO issued under this assistance listing. The remaining one-third of available funds are disbursed as a competitive, supplemental grant, based on criteria specified by the legislation. All qualified applications will be forwarded to an objective review committee. Based on the recommendations of the objective review committee, the HRSA program official with delegated authority is responsible for final selection and funding decisions. In addition, Minority AIDS Initiative (MAI) funds available under Section 2693 of the Public Health Service Act are disbursed on a formula basis together with the Formula and Supplemental awards as required by the legislation. Notification is made in writing by a Notice of Award (NOA). Contact the headquarters or regional location, as appropriate for application deadlines Approximately 6 months. Not applicable. Not applicable. Applications for supplemental funds must meet the review criteria outlined in the Notice of Funding Opportunity for the applicable period of performance. Not less than 75 percent of grant funds remaining after reserving funds for administration and clinical quality management must be used to provide core medical services. Core medical services include: AIDS Drug Assistance Program Treatments, AIDS Pharmaceutical Assistance, Early Intervention Services, Health Insurance Premium and Cost Sharing Assistance for Low-Income Individuals, Home and Community-Based Health Services, Home Health Care, Hospice, Medical Case Management (including treatment adherence services), Medical nutritional Therapy, Mental Health Services, Oral Health Care, Outpatient/Ambulatory Health Services, Substance Abuse Outpatient Care. The remaining 25 percent may be used for support services, including: Child Care Services, Emergency Financial Assistance, Food Bank/Home Delivered Meals, Health Education/Risk Reduction, Housing, Legal Services, Linguistic Services, Medical Transportation, Non-Medical Case Management Services, Outreach Services, Permanency Planning, Psychosocial Support Services, Referral for Health Care and Support Services, Rehabilitation Services, Respite Care, and Substance Abuse Services (residential) that support a person with HIV to achieve better health outcomes. An EMA/TGA shall use a percentage of the grant, determined by the percentage of women, infants, children, and youth with HIV/AIDS in the jurisdiction, to provide core medical and support services to infants, children, youth, and women with HIV. Funds may not be used to make payments for any item or service to the extent that payment has been made, or can reasonably be expected to be made, with respect to that item or service under any State compensation program, insurance policy, Federal or State health benefits program or by any entity that provides health services on a prepaid basis (except for a program administered by or providing the services to the Indian Health Service). Funds may not be used to purchase or improve land, or to purchase, construct or make permanent improvement to any building except for minor remodeling. Funds may not be used to make cash payments to intended recipients of Ryan White HIV/AIDS Program (RWHAP) services. Funds may not be used for pre-exposure prophylaxis (PrEP) or non-occupational post-exposure prophylaxis (nPEP) medications or the related medical services, as outlined in the June 22, 2016 Program Letter. Additionally, the purchase of sterile needles or syringes for the purposes of hypodermic injection of any illegal drug is not allowable. Some aspects of Syringe Services Programs are allowable with HRSA's prior approval and in compliance with HHS and HRSA policy (see: https://www.hiv.gov/federal-response/policies-issues/syringe-services-programs). An EMA/TGA may not use more than 10 percent of amounts received under this grant for administration. Clinical Quality Management expenditures are not included in the administrative or planning and evaluation costs, but are subject to a cap of the lesser of 5 percent of amounts received under the grant or $3,000,000. In addition, the aggregate total of administrative expenditures for subrecipients, including all indirect costs, may not exceed ten (10) percent of the aggregate amount of all subawards. Performance Reports: Final Performance Report (if applicable) IIn accordance with the provisions of 45 CFR 75, Subpart F - Audit Requirements, non-Federal entities that expend financial assistance of $750,000 or more in Federal awards will have a single or a program-specific audit conducted for that year. Non-Federal entities that expend less than $750,000 a year in Federal awards are exempt from Federal audit requirements for that year, except as noted in 45 CFR 75. Recipients are required to maintain financial records 3 years after the date they submit the final FFR. If any litigation, claim, negotiation, audit or other action involving the award has been started before the expiration of the 3-year period, the records shall be retained until completion of the action and resolution of all issues which arise from it, or until the end of the regular 3-year period, whichever is later. Statutory Formula: Title 42 U.S.C. Chapter § 300ff-13 Part (a)

Matching requirements are not applicable to this assistance listing.

This program has MOE requirements, see funding agency for further details. Additional Information: The RWHAP legislation requires Part A recipients to maintain, as a Condition of Award, political subdivision expenditures within the eligible area for HIV-related core medical services and support services at a level equal to the 1-year period preceding the fiscal year for which the recipient is applying to receive a Part A grant. MAI formula funds are based on the number of reported and confirmed living minority cases of HIV/AIDS for the most recent calendar year. Grants are awarded for a 12-month budget period, within a three-year period of performance. Recipients draw down funds, as necessary, from the Payment Management System (PMS). PMS is the centralized web based payment system for HHS awards. None/Not specified. Chrissy Abrahms-Woodland, Director,
5600 Fishers Lane, Room 9W12
Rockville, MD 20857 US
Chrissy.Abrahms@hrsa.hhs.gov
Phone: (301) 443-1373 https://ryanwhite.hrsa.gov/ 75-0350-0-1-550 (Project Grants) FY 22$670,487,460.00; FY 23 est $669,526,962.00; FY 24 FY 21$621,430,104.00; FY 20$626,910,358.00; FY 19$628,321,646.00; FY 18$624,346,301.00; FY 17$629,697,949.00; FY 16$627,786,733.00; - FY 22: $2,832,860 to $ 93,314,502 FY23: $2,862,396 to $93,371,588 FY24: $2,862,396 to $93,371,588 All HRSA awards are subject to the Uniform Administrative Requirements, Cost Principles, and Audit Requirements at 45 CFR part 75. As per 45 CFR part 75.201 and 301, recipients may use a fixed-award instrument to obtain services based on a reasonable estimate of actual cost and based on performance and results related to improvement of program outcomes. HRSA awards are subject to the requirements of the HHS Grants Policy Statement (HHS GPS) that are applicable based on recipient type and purpose of award. The HHS GPS is available at http://www.hrsa.gov/grants. Not applicable.